PHARMING GROUP NV (PHGN.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:PHGN - NL0010391025 - Common Stock

1.74 EUR

-0.04 (-2.25%)

Last: 1/28/2026, 7:00:00 PM

Fundamental Rating

We assign a fundamental rating of 5 out of 10 to PHGN. PHGN was compared to 85 industry peers in the Biotechnology industry. Both the profitability and the financial health of PHGN get a neutral evaluation. Nothing too spectacular is happening here. PHGN is not valued too expensively and it also shows a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year PHGN has reported negative net income.
In the past year PHGN had a positive cash flow from operations.
In multiple years PHGN reported negative net income over the last 5 years.
In multiple years PHGN reported negative operating cash flow during the last 5 years.

1.2 Ratios

With a decent Return On Assets value of 0.08%, PHGN is doing good in the industry, outperforming 68.24% of the companies in the same industry.
PHGN has a better Return On Equity (0.14%) than 72.94% of its industry peers.
With an excellent Return On Invested Capital value of 6.65%, PHGN belongs to the best of the industry, outperforming 82.35% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	0.08%
ROE	0.14%
ROIC	6.65%

ROA(3y)-0.68%

ROA(5y)2.2%

ROE(3y)-1.17%

ROE(5y)5.07%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PHGN has a better Profit Margin (0.11%) than 69.41% of its industry peers.
Looking at the Operating Margin, with a value of 10.06%, PHGN is in the better half of the industry, outperforming 78.82% of the companies in the same industry.
PHGN has a Gross Margin of 89.90%. This is amongst the best in the industry. PHGN outperforms 83.53% of its industry peers.
PHGN's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	10.06%
PM (TTM)	0.11%
GM	89.9%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.48%

GM growth 5Y0.17%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so PHGN is still creating some value.
The number of shares outstanding for PHGN has been increased compared to 1 year ago.
PHGN has more shares outstanding than it did 5 years ago.
PHGN has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 1.17, we must say that PHGN is in the distress zone and has some risk of bankruptcy.
PHGN has a better Altman-Z score (1.17) than 61.18% of its industry peers.
PHGN has a debt to FCF ratio of 2.49. This is a good value and a sign of high solvency as PHGN would need 2.49 years to pay back of all of its debts.
PHGN has a better Debt to FCF ratio (2.49) than 82.35% of its industry peers.
A Debt/Equity ratio of 0.46 indicates that PHGN is not too dependend on debt financing.
PHGN has a Debt to Equity ratio of 0.46. This is comparable to the rest of the industry: PHGN outperforms 54.12% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.46
Debt/FCF	2.49
Altman-Z	1.17

ROIC/WACC1.19

WACC5.57%

2.3 Liquidity

PHGN has a Current Ratio of 3.16. This indicates that PHGN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PHGN (3.16) is better than 63.53% of its industry peers.
A Quick Ratio of 2.39 indicates that PHGN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.39, PHGN is in line with its industry, outperforming 54.12% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.16
Quick Ratio	2.39

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 96.30% over the past year.
The Revenue has grown by 26.78% in the past year. This is a very strong growth!
The Revenue has been growing by 10.64% on average over the past years. This is quite good.

EPS 1Y (TTM)96.3%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%600%

Revenue 1Y (TTM)26.78%

Revenue growth 3Y14.33%

Revenue growth 5Y10.64%

Sales Q2Q%30%

3.2 Future

The Earnings Per Share is expected to grow by 53.48% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 8.97% on average over the next years. This is quite good.

EPS Next Y111.44%

EPS Next 2Y85.83%

EPS Next 3Y65.17%

EPS Next 5Y53.48%

Revenue Next Year26.31%

Revenue Next 2Y14.87%

Revenue Next 3Y10.89%

Revenue Next 5Y8.97%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Forward Earnings ratio of 79.64, PHGN can be considered very expensive at the moment.
PHGN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. PHGN is cheaper than 69.41% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of PHGN to the average of the S&P500 Index (25.72), we can say PHGN is valued expensively.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	79.64

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PHGN indicates a rather cheap valuation: PHGN is cheaper than 97.65% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHGN indicates a rather cheap valuation: PHGN is cheaper than 97.65% of the companies listed in the same industry.

		Industry Rank	Sector Rank
P/FCF	2.76
EV/EBITDA	1.46

4.3 Compensation for Growth

PHGN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PHGN's earnings are expected to grow with 65.17% in the coming years. This may justify a more expensive valuation.